


Exploitation of Palladium-Catalyzed Reductive Enyne Cyclization in the Synthesis of (-)-4a,5-Dihydrostreptazolin

Hironari Yamada, Sakae Aoyagi, and Chihiro Kibayashi*

School of Pharmacy, Tokyo University of Pharmacy & Life Science
 Horinouchi, Hachioji, Tokyo 192-03, Japan

Abstract: Hydroxyl-promoted reductive cyclization of enyne compounds catalyzed by Pd(OAc)₂-BBEDA was explored and found to effect constructing the pyridine framework with the alkylidene appendage. This methodology was applied to the stereoselective synthesis of (-)-4a,5-dihydrostreptazolin. Copyright © 1996 Elsevier Science Ltd


We have currently reported¹ the stereoselective synthesis of antibiotic (+)-streptazolin (**1**) utilizing a palladium-based approach for constructing the pyridine core skeleton bearing the Z ethylidene group. This approach involves palladium-catalyzed enyne cycloisomerization which has broadly been developed by Trost.²




The mechanism of this catalytic reaction can be accounted for by a pathway invoking formation of a hydridopalladium(II) species, L₂Pd(H)X, followed by hydropalladation of the carbon-carbon triple bond to generate **6** with pentacoordinate Pd(II)³ that initiates carbopalladation to form the cyclic intermediate **7**. Subsequent pathway involving β-elimination (path a) generates the 1,3- and/or 1,4-diene products (**8** and/or **9**) and regenerates the catalyst, L₂Pd(H)X (eq 1). On the other hand, when the palladium-catalyzed reaction is carried out in the presence of an appropriate hydride source, hydride exchange (path b) followed by reductive elimination occurs to produce the exocyclic olefin **11**.⁴

While the nonreductive palladium-catalyzed enyne cyclization (eq 1) has extensively been studied,² relatively limited investigations of the reductive enyne cyclization (eq 2) and its synthetic use⁵ have appeared. In this context, we became interested in developing an efficient protocol for the reductive palladium-catalyzed enyne cyclization applicable to the synthesis of 4a,5-dihydrostreptazolin (**4**), which was anticipated to exhibit enhanced stability in contrast to streptazolin (**1**) having a tendency to undergo polymerization in concentrated form due to the presence of the conjugated diene part. Additionally, we were intrigued by the potential of **4** as a therapeutic agent. These expectations were based on the fact that the acetate derivative **3** of 5,8-dihydrostreptazolin (**2**) has been recognized to be highly stable and found to exhibit marginal antibacterial and antifungal activity.⁶

To test the viability of this cyclization approach using the reductive cyclization methodology the racemic enyne compounds **18**, **19**, and **21** were first prepared as substrates as outlined in Scheme 1. The N-acetyl dihydropyridone **13**, prepared⁷ from 4-propoxy pyridine (**12**), was converted to the 2-allyltetrahydropyridine **14** by reduction with NaBH₄/CeCl₃ followed by Lewis acid induced allylation.⁸ The aldehyde **15** obtained via



hydroboration followed by catalytic TPAP oxidation⁹ underwent dibromomethylenation to give **16**. Treatment of **16** with 2 equiv of BuLi resulted in *in situ* generation of the lithium acetylide **17**, which on acidic treatment or reaction with iodomethane provided the enynes with the terminal or inner acetylenes, **18** or **19**, respectively. On the other hand, the aldehyde **20** obtained by oxidative cleavage of the olefin in **14** was treated with the cerium(III) reagent, prepared from 1-propynyllithium and CeCl₃,¹⁰ to afford a ca. 1:1 epimeric mixture of the alcohols, which was separated by column chromatography on silica gel (hexane–EtOAc, 10:1) to yield **21**.



Scheme 1: (a) CbzCl, NaBH₄, MeOH, –80 °C, then 1 N HCl (76%); (b) (i) NaBH₄, CeCl₃, MeOH, 0° C; (ii) CH₂=CHCH₂SiMe₃, TiCl₄, CH₂Cl₂, –80 °C (88%); (c) (i) 9-BBN, THF, then 3 N NaOH, 30% H₂O₂ (83%); (ii) Pr₄NRuO₄ (TPAP) (5 mol %), *N*-methylmorpholine *N*-oxide, CH₂Cl₂, rt (67%); (d) CBr₄, Ph₃P, CH₂Cl₂, rt (94%); (e) BuLi/hexane, THF, –80 °C; (f) to give **18**: 1 N HCl (85% from **16**); (g) to give **19**: MeI, HMPA (76% from **16**); (h) OsO₄–NaIO₄, dioxane–H₂O (52%); (i) MeC≡CCeCl₂, THF, –80 °C, then chromatographic separation of the alcohol epimers (25%).









The enynes **18**, **19** and **21** were subjected to 5 mol % of Pd(OAc)₂ and 5 mol % of *N,N'*-bis(benzylidene)ethylenediamine (BBEDA) in the presence of the hydride source in the appropriate solvent including 2 equiv of acetic acid (reflux) to afford the results shown in Table 1. Upon treatment of **18** in the presence of Bu₃SnH as a hydride source in benzene, chemoselective semihydrogenation of the acetylene¹¹ was observed to form the diene **22** (entry 1). When the reaction of **18** was carried out using hydride from polymethylhydrosiloxane (PMHS) instead of Bu₃SnH in benzene (reflux, 20 min), reductive cyclization smoothly proceeded to produce the pyridine **23** in 78% yield (entry 2). In this case, when the same reaction was performed in the absence of acetic acid, however, **23** was formed only in 5% yield. These results obtained using PMHS are consistent with a mechanism discussed above for reductive cyclization according to path b (eq 2) which involves regeneration of the active catalyst, L₂Pd(H)OAc, by addition of acetic acid to Pd(0). In the

case of the reaction using Bu_3SnH as a hydride source (entry 1), in the competing process between hydride reduction of palladium (in **6**) and cyclization (**6** \rightarrow **7**) the former process would predominate.

In marked contrast with the terminal acetylene **18**, the reaction of the internal acetylene **19** was found to be sluggish. Thus, upon prolonged heating of **19** in the presence of PMHS in benzene (reflux, 9 h), the reductive cyclization product **25** with pure *E* ethylidene stereochemistry was obtained in a low yield (26%) together with the semihydrogenation product **24** (48%) purely in *Z* form as a major product (entry 4). When this reaction was performed using PMHS in toluene (reflux, 7 h), reductive cyclization proceeded without the competitive formation of **24**, providing **25** in 58% yield along with 29% recovered starting material (entry 5). By using the same conditions as in entry 5 but replacing PMHS as a hydride donor with Ph_2SiH_2 **19** underwent exclusively semihydrogenation to yield **24** (entry 3).


When a benzene solution of the propargyl alcohol **21** was treated under the same catalytic conditions as above for **19**, the rate of the cyclization reaction was dramatically improved; thus as shown in entry 6 the reaction was completed in 10 min ! instead of 9 h (benzene) or 7 h (toluene) with **19**, providing the pyridine **26**. The fact that unusually rapid cyclization occurred, despite the expectation that the internal acetylene serves to be sluggish to cyclization as seen above, would be rationalized by eq 3 invoking precoordination between Pd

Table 1. Palladium-catalyzed reaction of the enynes **18**, **19**, and **21** in the presence of hydride reagents.^a


Entry	Enyne	Hydride Reagent (Equiv ^b)	Solvent	Time	Product (% Yield ^c)
1		Bu_3SnH (3)	benzene	2 h	 22 (42)
2	18	PMHS (10)	benzene	20 min	 23 (78)
3		Ph_2SiH_2 (6)	toluene	12 h	 24 (78)
4	19	PMHS (10)	benzene	9 h	24 (48) +  25 (26)
5	19	PMHS (10)	toluene	7 h	25 (58)
6		PMHS (10)	benzene	10 min	 26 (50)

^aAll reactions were conducted with $\text{Pd}(\text{OAc})_2$ -BBEDA (5 mol %) in the presence of the hydride source in the appropriate solvent including AcOH (2 equiv) at reflux temperature. ^bBased on hydride ion. ^cIsolated yield after chromatographic purification.

and the hydroxyl group.¹² Such chelate formation (**28**) would facilitate subsequent hydropalladation to the internal acetylene to form **29** with excellent regiocontrol, wherein the Pd–C bond is positioned suitably for the following carbopalladation process to form ring as illustrated above in eqs 1 and 2 (**6** → **7**).



Having secured hydroxyl-promoted reductive cyclization to elaborate the pyridine framework, we next turned to the synthesis of 4a,5-dihydrostreptazolin (**4**) utilizing the chiral enyne **30**, which we had described earlier,¹ as a precursor for reductive cyclization (Scheme 2). Selective removal of the benzyl protecting groups was conducted by exposure of **30** to BCl_3 at $-10\text{ }^\circ\text{C}$ to furnish the glycol **31** in 75% yield. Subsequent basic treatment of **31** resulted in the cyclic urethane **32** in 88% yield. The synthetic protocol used for the reductive cyclization of the propargyl alcohol **21** (Table 1, entry 6) was now successfully applied to **32**, which effected the stereoselective ring formation to afford in one step (–)-4a,5-dihydrostreptazolin (**4**), isolated as stable colorless needles, mp $154\text{--}155\text{ }^\circ\text{C}$ (EtOAc–hexane); $[\alpha]_D^{23} -24.3$ (c 0.54, CHCl_3), in 58% yield. The stereostructure and *Z* geometry of **4** were unambiguously assigned by ^1H NOE experiments.



Scheme 2: (a) BCl_3 , CH_2Cl_2 , $-10\text{ }^\circ\text{C}$, 15 min (75%); (b) 20% KOH , *i*-PrOH, rt (88%); (c) $\text{Pd}(\text{OAc})_2$ –BBEDA (10 mol %), PMHS (10 equiv), AcOH (2 equiv), benzene, reflux, 30 min (58%).

Further works on biological evaluation of synthetic (–)-4a,5-dihydrostreptazolin (**4**) and extension of this reductive cyclization methodology to the stereoselective synthesis of natural alkaloids are underway.

References and Notes

1. Yamada, H.; Aoyagi, S.; Kibayashi, C. *J. Am. Chem. Soc.* **1996**, *118*, 1054–1059.
2. For recent reviews, see: (a) Trost, B. M. *Acc. Chem. Res.* **1990**, *23*, 34–42. (b) Trost, B. M. *Angew. Chem. Int. Ed. Engl.* **1995**, *34*, 259–281.
3. Maitlis, P. M.; Espinet, P.; Russell, M. J. H. In *Comprehensive Organometallic Chemistry*; Wilkinson, G., Ed.; Pergamon: Oxford, 1982; Vol. 6, pp 233–242.
4. Trost, B. M.; Rise, F. *J. Am. Chem. Soc.* **1987**, *109*, 3161–3163.
5. For application to natural product synthesis, see: (a) Trost, B. M.; Braslau, R. *Tetrahedron Lett.* **1988**, *29*, 1231–1234. (b) Trost, B. M.; Edstrom, E. D. *Angew. Chem. Int. Ed. Engl.* **1990**, *29*, 520–521. (c) Wender, P. A.; McDonald, F. E. *J. Am. Chem. Soc.* **1990**, *112*, 4956–4958. (d) Toyota, M.; Asoh, T.; Fukumoto, K. *Tetrahedron Lett.* **1996**, *37*, 4401–4404.
6. Drautz, H.; Zähler, H.; Kupfer, E.; Keller-Schierlein, W. *Helv. Chem. Acta* **1981**, *64*, 1752–1765.
7. This procedure is according to: Raucher, S.; Macdonald, J. E. *Synth. Commun.* **1980**, *10*, 325–331.
8. Kozikowski, A. P.; Park, P. *J. Org. Chem.* **1984**, *49*, 1674–1676.
9. For a review, see: Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. *Synthesis* **1994**, 639–666.
10. Suzuki, M.; Kimura, Y.; Terashima, S. *Chem. Lett.* **1984**, 1543–1546.
11. Trost, B. M.; Braslau, R. *Tetrahedron Lett.* **1989**, *30*, 4657–4660.
12. Negishi, E.; Iyer, S.; Rousset, C. *J. Tetrahedron Lett.* **1989**, *30*, 291–294.